Categories
Blood Cancer

BELINDA: Tisagenlecleucel in B-cell NHL [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, discusses results from the Phase III BELINDA trial (NCT03570892), which assessed tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with aggressive B-cell non-Hodgkin lymphoma. The primary endpoint, which was event-free survival, was not met, and tisa-cel was not superior to the current standard of care. Dr Bishop highlights the time taken for the therapy to be administered, bridging therapy, and the dosage of lymphodepleting chemotherapy to be factors affecting the trial results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Breast Cancer

PROCURE: Genomic signatures and adjuvant chemotherapy for breast cancer in Europe [Video]

Giuseppe Curigliano, MD, PhD, University of Milan and European Institute of Oncology, Milan, Italy, discusses the PROCURE project, a survey across European investigators about use of genomic signatures to make decisions about adjuvant chemotherapy use in early breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

Challenges of treating patients with breast cancer with leptomeningeal metastasis [Video]

Gaia Griguolo, MD, University of Padova, Padova, Italy, discusses the challenges of treating patients with breast cancer who develop leptomeningeal metastases, and covers some of the current treatment options for these patients. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

Impact of genomic testing on treatment decision-making in breast cancer [Video]

Corey Speers, MD, PhD, University of Michigan Medicine, Ann Arbor, MI, discusses how the availability of genomic testing has affected treatment decision-making over the last decade. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

16-gene signature identifies early-stage invasive breast cancer patients who may omit radiotherapy [Video]

Corey Speers, MD, PhD, University of Michigan Medicine, Ann Arbor, MI, presents findings of a study using a 16-gene signature (POLAR) to identify early-stage invasive breast cancer patients who may omit radiotherapy. The POLAR genomic signature accurately identified patients with a low risk of locoregional recurrence without significant benefit from adjuvant radiotherapy. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

Final results from PALLAS: adjuvant palbociclib in HR+/HER2- early breast cancer [Video]

Michael Gnant, MD, Medical University of Vienna, Vienna, Austria, shares the final results from the randomized, Phase III PALLAS trial (NCT02513394). PALLAS investigated whether the addition of the CDK4/6 inhibitor, palbociclib, to adjuvant endocrine therapy improves outcomes over endocrine therapy alone in patients with hormone receptor-positive, HER2-negative early breast cancer. The addition of palbociclib did not improve survival endpoints in this patient population; whether the addition of CDK4/6 inhibition to particular subgroups of patients is being investigated. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Blood Cancer

CAR-T therapy in multiple myeloma: research blind spots [Video]

CAR T-cell therapy has been shown to elicit high-quality responses in patients with multiple myeloma. Positive data from the pivotal Phase II KarMMa trial led to the approval of idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in patients with heavily pretreated relapsed/refractory myeloma, and ongoing trials are investigating the utility of CAR-T versus standard of care regimens in earlier lines of treatment. Andrew Cowan, MD, University of Washington, Seattle, WA, discusses the blind spots in myeloma CAR-T research, highlighting key topics such as treatment sequencing, combination studies, and retreatment with BCMA-targeted therapies. This interview took place at during 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Breast Cancer

Future research directions for breast cancer [Video]

Giuseppe Curigliano, MD, PhD, University of Milan and European Institute of Oncology, Milan, Italy, discusses what he thinks are the most important trials and future research directions in ER-positive, HER2-positive, and triple-negative breast cancer. Oral selective estrogen receptor degraders (SERDs) were an exciting topic at SABCS 2021, with promising data being presented. Dr Curigliano also discusses the NATALEE (NCT03701334) and DESTINY-Breast06 (NCT04494425) trials. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Blood Cancer

Optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent lines [Video]

Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses the findings of a study investigating optimal treatment sequencing in multiple myeloma. With the available options for treatment expanding rapidly, determining the best strategies for upfront treatment and subsequent lines of therapy is of critical importance. In this analysis, the clinical value of daratumumab (DARA) first line compared to later lines was examined in patients with newly diagnosed transplant-ineligible multiple myeloma, since it is unclear where it performs optimally. It was shown that using DARA, lenalidomide, and dexamethasone (D-Rd) first line substantially improved overall survival compared with delaying DARA-based treatment until second line. Due to higher attrition rates in second line and beyond, the results demonstrate that achieving the longest possible progression-free survival in first line is key to optimize overall survival outcomes and therefore, saving DARA to later lines is a suboptimal approach. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of immunotherapy in multiple myeloma [Video]

Nina Shah, MD, University of California, San Francisco, CA, provides her insights on the future of multiple myeloma treatment. Multiple advancements have been made in recent years, especially with the development of immunotherapies. In addition to existing monoclonal antibodies such as daratumumab and isatuximab, chimeric antigen receptor (CAR) T-cell therapies including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) represent alternative therapies for patients with relapsed/refractory multiple myeloma. Dr Shah additionally highlights the development of bispecific T-cell engagers (BiTEs), as well moving immunotherapies into the frontline setting. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Breast Cancer

Recent breast cancer updates from SABCS 2021 [Video]

Nadeem Bilani, MD, Mount Sinai Morningside, New York, NY, provides an overview of recent updates in breast cancer presented at the San Antonio Breast Cancer Symposium (2021) hybrid meeting, including the evaluation of novel antibody-drug conjugates, as well as further updates on the use of immunotherapy in breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Blood Cancer

The role of CAR-T therapy in hematologic malignancies [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, describes advances in chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Data from the JULIET (NCT02445248), TRANSFORM (NCT03575351), BELINDA (NCT03570892), ZUMA-1 (NCT02348216), and ZUMA-7 (NCT03391466) trials have demonstrated CAR T-cell therapy as a promising frontline therapy in non-Hodgkin lymphoma. Dr Bishop additionally highlights updates in multiple myeloma and acute lymphoblastic leukemia (ALL), as well as strategies to manage CAR T-cell toxicity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.